Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Predicting the end of Covid-19 infection for various countries using a stochastic agent-based model taking into account vaccination rates and the new mutant

Manfred Eissler
doi: https://doi.org/10.1101/2021.04.22.21255941
Manfred Eissler
Former head of the general medicine department (research) at the University of Tübingen
Roles: Doctor of medicine and graduate of physics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dr.eissler{at}t-online.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Using a stochastic, agent-based model, the course of infection since the first occurrence of a Covid-19 infection is simulated for various countries, taking into account the new, more infectious mutant and the vaccinations. The simulation shows that the course of infection for the United Kingdom (UK) and Israel is surprisingly good. For the other countries, an end date for the infection can be predicted based on the course of the simulation. For Germany, the course is calculated in a second scenario, assuming a higher vaccination rate.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

no external funding was received

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

not mandatory

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The program and the data are available via the link provided. Attention: stochastic simulation, delivers random values!

https://www.magentacloud.de/share/sdgblo2l5w

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 26, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Predicting the end of Covid-19 infection for various countries using a stochastic agent-based model taking into account vaccination rates and the new mutant
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Predicting the end of Covid-19 infection for various countries using a stochastic agent-based model taking into account vaccination rates and the new mutant
Manfred Eissler
medRxiv 2021.04.22.21255941; doi: https://doi.org/10.1101/2021.04.22.21255941
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Predicting the end of Covid-19 infection for various countries using a stochastic agent-based model taking into account vaccination rates and the new mutant
Manfred Eissler
medRxiv 2021.04.22.21255941; doi: https://doi.org/10.1101/2021.04.22.21255941

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3281)
  • Dentistry and Oral Medicine (362)
  • Dermatology (274)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
  • Epidemiology (13337)
  • Forensic Medicine (19)
  • Gastroenterology (896)
  • Genetic and Genomic Medicine (5128)
  • Geriatric Medicine (479)
  • Health Economics (781)
  • Health Informatics (3251)
  • Health Policy (1137)
  • Health Systems and Quality Improvement (1189)
  • Hematology (427)
  • HIV/AIDS (1012)
  • Infectious Diseases (except HIV/AIDS) (14611)
  • Intensive Care and Critical Care Medicine (908)
  • Medical Education (475)
  • Medical Ethics (126)
  • Nephrology (521)
  • Neurology (4898)
  • Nursing (261)
  • Nutrition (725)
  • Obstetrics and Gynecology (879)
  • Occupational and Environmental Health (795)
  • Oncology (2515)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (346)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (537)
  • Pediatrics (1297)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (554)
  • Psychiatry and Clinical Psychology (4189)
  • Public and Global Health (7482)
  • Radiology and Imaging (1700)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (478)
  • Sexual and Reproductive Health (495)
  • Sports Medicine (424)
  • Surgery (545)
  • Toxicology (71)
  • Transplantation (235)
  • Urology (203)